Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06OMK
|
||||
| Former ID |
DAP000162
|
||||
| Drug Name |
Tacrolimus
|
||||
| Synonyms |
Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; FK506
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Immunosuppressive Agents
|
||||
| Company |
Fujisawa; Sucampo
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C44H69NO12
|
||||
| InChI |
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
|
||||
| InChIKey |
QJJXYPPXXYFBGM-LFZNUXCKSA-N
|
||||
| CAS Number |
CAS 104987-11-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
4572, 832905, 842004, 7887491, 7980719, 8150098, 10299743, 12013904, 14815954, 14889261, 24841759, 26703416, 26705532, 26705535, 26713140, 26715494, 26756858, 29216422, 36888289, 46506004, 47574395, 48020022, 50111459, 50111460, 53788265, 57404698, 74380484, 76558282, 85788970, 91011629, 92308089, 92310166, 92711966, 96025241, 99301078, 99302128, 99436940, 103164549, 103939344, 104178757, 104222107, 104634734, 109693101, 118048657, 119525750, 124757870, 124766122, 124892446, 124892447, 124892448
|
||||
| SuperDrug ATC ID |
D11AH01; L04AD02
|
||||
| SuperDrug CAS ID |
cas=109581933
|
||||
| Target and Pathway | |||||
| Target(s) | Calcineurin | Target Info | Inhibitor | [536119] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| Oocyte meiosis | |||||
| Apoptosis | |||||
| Wnt signaling pathway | |||||
| Axon guidance | |||||
| VEGF signaling pathway | |||||
| Osteoclast differentiation | |||||
| Natural killer cell mediated cytotoxicity | |||||
| T cell receptor signaling pathway | |||||
| B cell receptor signaling pathway | |||||
| Long-term potentiation | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Oxytocin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Amphetamine addiction | |||||
| Tuberculosis | |||||
| HTLV-I infection | |||||
| WikiPathways | Mitochondrial Gene Expression | ||||
| MAPK Signaling Pathway | |||||
| G Protein Signaling Pathways | |||||
| Cardiac Hypertrophic Response | |||||
| Fc epsilon receptor (FCERI) signaling | |||||
| Signaling by the B Cell Receptor (BCR) | |||||
| T-Cell Receptor and Co-stimulatory Signaling | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Spinal Cord Injury | |||||
| Alzheimers Disease | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| Opioid Signalling | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| Physiological and Pathological Hypertrophy of the Heart | |||||
| References | |||||
| Ref 537129 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | ||||
| Ref 541864 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6784). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.